Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Cazzola

Showing results (551-560 of 645) with videos related to

Pageof 65
Sort By:
NPJ Primary Care Respiratory Medicine|March 25, 2018
Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice settingRosarita Ferrara, Valentina Ientile, Carlo Piccinni, et al.
Blood|November 4, 2017
Gene expression and risk of leukemic transformation in myelodysplasiaYusuke Shiozawa, Luca Malcovati, Anna Gallì, et al.
Blood Advances|February 14, 2025
In vitro studies of human erythropoiesis using a 3D silk-based bone marrow model that generates erythroblastic islandsChristian A Di Buduo, Francesca Careddu, Samuele Metti, et al.
American Journal of Hematology|January 11, 2022
PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasmsJelena D Milosevic Feenstra, Roland Jäger, Fiorella Schischlik, et al.
Breathe (Sheffield, England)|June 28, 2023
Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022Daiana Stolz, Maria Gabriella Matera, Paola Rogliani, et al.
Blood|May 3, 2011
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progressionThorsten Klampfl, Ashot Harutyunyan, Tiina Berg, et al.
Blood|February 2, 2013
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemiaEsperanza Such, Ulrich Germing, Luca Malcovati, et al.
Blood|January 25, 2014
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II studyPaola Guglielmelli, Flavia Biamonte, Giada Rotunno, et al.
Cancer|November 22, 2013
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyureaSrdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, et al.
British Journal of Haematology|August 19, 2014
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia veraFederico Lussana, Alessandra Carobbio, Maria L Randi, et al.
Pageof 65

Showing results (551-560 of 645) with videos related to

Sort By:
Pageof 65
NPJ Primary Care Respiratory Medicine|March 25, 2018
Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice settingRosarita Ferrara, Valentina Ientile, Carlo Piccinni, et al.
Blood|November 4, 2017
Gene expression and risk of leukemic transformation in myelodysplasiaYusuke Shiozawa, Luca Malcovati, Anna Gallì, et al.
Blood Advances|February 14, 2025
In vitro studies of human erythropoiesis using a 3D silk-based bone marrow model that generates erythroblastic islandsChristian A Di Buduo, Francesca Careddu, Samuele Metti, et al.
American Journal of Hematology|January 11, 2022
PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasmsJelena D Milosevic Feenstra, Roland Jäger, Fiorella Schischlik, et al.
Breathe (Sheffield, England)|June 28, 2023
Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022Daiana Stolz, Maria Gabriella Matera, Paola Rogliani, et al.
Blood|May 3, 2011
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progressionThorsten Klampfl, Ashot Harutyunyan, Tiina Berg, et al.
Blood|February 2, 2013
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemiaEsperanza Such, Ulrich Germing, Luca Malcovati, et al.
Blood|January 25, 2014
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II studyPaola Guglielmelli, Flavia Biamonte, Giada Rotunno, et al.
Cancer|November 22, 2013
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyureaSrdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, et al.
British Journal of Haematology|August 19, 2014
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia veraFederico Lussana, Alessandra Carobbio, Maria L Randi, et al.
Pageof 65